Released Nov 13, 2024, after the close
10-Q filed Nov 13, 2024, 44 days after period end · 0000950170-24-126407
Q3 2024 · 10-Q
Revenue$8.52M$8.52M −49.7% vs Q3 2023−66.9% vs Q2 2024
Net Income-$48.79M-$48.79M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.59-$0.59 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$67,919,000N/M
Operating Cash Flowderived-$64,516,000N/M
Margins · derived
Operating margin-797.2%−537.1 pt vs Q3 2023
Net margin-572.6%−281.4 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $8.52M | $16.92M | $25.15M | $8.52M |
| Net Income | -$48.79M | -$49.28M | -$19.49M | -$30.90M |
| EPS Diluted | -$0.59 | -$0.81 | -$0.37 | -$0.67 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR